Aui Labs
Nonprofit profile at a glance
- EIN
- 371904234
- IRS 990 coverage
- 2024–2024
- Forms available
- Form 990 2024, Form 990-N 2023
- Location
- Vienna, VA, USA
- Phone
- 2024621676
- Rating
- 71
- Verdict
- SUPPORTED
- Rating confidence
- Moderate
- Sector
- Alliance/Advocacy Organizations
Reported finances
- Revenue
- $1,645,713
- Expenses
- $1,425,749
- Assets
- $799,470
- Liabilities
- $579,506
Source: IRS Form 990. Selected filing: tax year 2024. Amounts in USD.
Leadership & pay
4 people listed
Executive titles in this filing
- ADAM COHEN (CEO/TRUSTEE)
Highest reported compensation
- ADAM COHEN (CEO/TRUSTEE): $609,012 total reported compensation
- MARK MACKEY (CORPORATE SECRETARY/TREASURER): $338,825 total reported compensation
Source: IRS Form 990. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.
Overview
Mission
Aui labs is engaged in exploring ways to deliver first in class management and operational support to federally funded research and development centers (ffrdcs).
What it reported doing in 2024
On april 1, 2025, aui labs was selected by the industrial macromolecular crystallography association collaborative access team ("imca-cat") to operate the imca-cat educational and scientific research facility. Imca-cat is located at argonne national laboratory in lemont, Illinois, and hosts the advanced photon source ("aps"). Aui labs began operating the imca-cat facility immediately after its selection, operating in a role similar to the role carried on by aui in numerous other instances. The aps-and imca-cat more broadly-is critical to the development of lifesaving medications and revolutionary therapeutics for treating disease. By managing the imca-cat facility, aui labs drives the development of innovative and cost-effective medications that transform general public's health and wellness. Simultaneously, aui labs is researching and implementing innovative approaches to medical research education at the facility. Users of the facility include both pharmaceutical development companies and members of the general public. A minimum of half of the usage time for the facility is required to be set aside for members of the general public.
Operating model
- Revenue model
- Earned-program. 100% of the money available for current operations came from fees and other program revenue.
- Distribution model
- Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.
The verdict
SUPPORTED - A large share of available resources goes toward mission work and most voting board members are independent. Few specific pay-setting methods are documented in the filing; unanswered boxes are not proof of absence and some filing-based governance responses are negative or unanswered.
Rating breakdown
- Financial Efficiency: 81
- Transparency & Controls: 60
- Accountability: 91
- Sustainability: 45
- Growth: NotEnoughData
Detailed rating inputs
Financial Efficiency
- Mission deployment rate: 85.7%; rating input score 86
- Program expense ratio: 99%; rating input score 99
- Fundraising efficiency: Limited
Transparency & Controls
- Consistency checks: 100%; rating input score 100; 63rd percentile among comparable filings
- Pay-setting controls: 0 of 6 controls in place; rating input score 0
- Compensation committee: Missing
- Independent consultant: Missing
- Other Form 990s reviewed: Missing
- Written employment contract: Missing
- Compensation survey or study: Missing
- Board or committee approval: Missing
- Foreign activity oversight: Limited
- Grant itemization coverage: Limited
- Major donor itemization: Limited
- Related-party transparency: Limited
Accountability
- Independent voting board: 100%; rating input score 100; 63rd percentile among comparable filings
- Governance controls: 7 of 9 controls in place; rating input score 78
- Conflict-of-interest policy: Pass
- Whistleblower policy: Pass
- Document-retention policy: Pass
- CEO compensation review process: Fail
- Other executive compensation review process: Fail
- Form 990 shared with the board: Pass
- Board meeting minutes documented: Pass
- Audit committee oversight: Pass
- Independent financial-statement audit: Pass
Sustainability
- Operating margin: 13.4%; rating input score 67; 67th percentile among comparable filings
- Total-asset coverage ratio: 0.56; rating input score 26; 26th percentile among comparable filings
- Liabilities to assets ratio: 0.72; rating input score 10; 10th percentile among comparable filings
- Officer compensation ratio: 8.2%; rating input score 43; 43rd percentile among comparable filings
Growth
- Program expense growth: Limited
- Revenue growth: Limited
- Asset growth: Limited
Details
- Where the money goes: 85.7% of revenue deployed · 99% of spending went to programs
- Governance: 4 of 4 board members independent · 7 of 9 filing controls reported
- Programs: 1 filed program accomplishment · $1.4M in reported program spending
- Leadership: top reported pay $609K · 4 people listed · 0 of 6 pay-setting controls reported
- Highest-paid contractors: 1 contractor listed · $274K reported
- Consistency: 20 of 20 current checks pass
- Schedules: 5 filed schedules · includes executive pay
- Contacts: How to reach this organization
- Related organizations: 1 filed related-organization link
- Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
Key Signals
Signals prioritize questions for review. They are not findings of misconduct.
- High — Transparency & Controls: Pay-setting controls scored 0/100.
- Review — Accountability: Governance controls: 2 of 9 not reported.
- High — Sustainability: Total-asset coverage ratio scored 26/100.
- High — Sustainability: Liabilities to assets ratio scored 10/100.
- Moderate — Sustainability: Officer compensation ratio scored 43/100.